Tiziana Life Sciences Announces Date of Annual General Meeting 2022
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its 2022 Annual General Meeting scheduled for December 29, 2022. Shareholders must vote by the record date of November 30, 2022. Relevant documents, including the agenda and financial statements, have been sent via mail and are available on the company's website. Tiziana is a clinical-stage biopharmaceutical firm focusing on innovative drug delivery methods for immunotherapy. Its lead candidates include the intranasal foralumab and milciclib, which have shown promising safety and efficacy in clinical studies.
- Tiziana's drug delivery technologies offer safer, more effective alternatives to traditional IV methods.
- Lead candidates intranasal foralumab and milciclib have demonstrated favorable safety profiles in clinical studies.
- None.
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting and https://ir.tizianalifesciences.com/financial-information/annual-reports respectively.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
FAQ
When is the Tiziana Life Sciences Annual General Meeting?
What is the record date for voting at the TLSA Annual General Meeting?
Where can I find Tiziana Life Sciences' financial statements?
What are Tiziana's lead drug candidates?
What therapeutic approach does Tiziana Life Sciences focus on?
